Discover Who Qualifies for Ozempic: Your Path to a Healthier You

Last reviewed: May 14, 2026

Last updated: May 14, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonist eligibility extends well beyond body mass index thresholds. Clinical qualification typically requires either type 2 diabetes diagnosis, documented cardiovascular disease, or obesity with weight-related comorbidities. The FDA expanded indication framework recognizes that metabolic phenotypes vary significantly across individuals, making provider evaluation essential.

Determining candidacy involves assessing multiple biomarkers: fasting glucose, HbA1c levels, blood pressure, lipid panels, and cardiovascular risk scores. PlexusDx's precision wellness approach integrates clinical assessment with genetic predisposition insights, helping patients and providers make informed treatment decisions grounded in evidence rather than assumptions.

Clinical Markers That Influence GLP-1 Treatment Consideration

Provider evaluation typically begins with metabolic assessment. Key markers include fasting glucose (≥100 mg/dL suggests prediabetes), HbA1c (≥5.7% indicates glucose control concerns), and waist circumference (independent cardiovascular risk factor). Blood pressure and lipid abnormalities also inform candidacy discussions.

Cardiovascular history significantly impacts qualification criteria. Patients with established coronary artery disease, stroke history, or heart failure may qualify independently of BMI. Recent guidelines recognize GLP-1 agents reduce cardiovascular events in high-risk populations, shifting eligibility focus toward metabolic and vascular risk stratification rather than weight alone.

Multi-Factor Eligibility Framework for Provider Assessment

Clinical candidacy requires integrating multiple parameters rather than relying on single metrics. This framework helps providers and patients structure eligibility conversations around documented metabolic dysfunction, cardiovascular risk, weight-related complications, and individual treatment goals. Evidence supports individualized assessment over algorithmic cutoffs.

Clinical Category	Typical Assessment Parameters
Metabolic Status	Fasting glucose >100 mg/dL, HbA1c ≥5.7%, insulin resistance markers
Weight-Related Factors	BMI ≥27 with comorbidities OR ≥30 regardless, waist circumference, functional limitations
Cardiovascular Risk	Blood pressure ≥130/80, abnormal lipid panel, established CVD history, family risk
Diabetes Status	Type 2 diabetes diagnosis, inadequate control on current medications, progression risk

How Genetic Predispositions in Peptide Pathways Inform Eligibility

Individual genetic variation in GLP-1 receptor signaling pathways may influence metabolic phenotype and treatment response patterns. The Precision Peptide Genetic Test examines key variants (GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, MC4R rs17782313) that show predispositions in appetite regulation and glucose metabolism. These insights may help contextualize individual metabolic profiles.

Genetic predispositions do not predict exact medication response or guarantee eligibility—rather, they may provide context for understanding why certain individuals develop metabolic dysfunction patterns. When interpreted with clinical markers and qualified provider guidance, genetic insights can support more personalized conversations about treatment suitability and expected metabolic behaviors.

Essential Safety Considerations and Provider-Guided Eligibility

Certain medical conditions require careful provider evaluation before GLP-1 consideration. Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe pancreatitis, diabetic retinopathy, or kidney disease warrant specialist assessment. Medication interactions and pregnancy considerations also influence candidacy decisions.

Provider qualification assessment should include medication review, complete medical history, and discussion of realistic expectations. GLP-1 agents are not indicated for weight loss alone in patients without metabolic dysfunction or cardiovascular risk. Professional medical evaluation remains essential—genetic testing and biomarkers inform conversation, but cannot replace clinical judgment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines predispositions in key peptide pathway variants linked to metabolic regulation. Understanding your genetic profile in GLP1R, GIPR, FTO, and MC4R pathways may help provide context for why your metabolic phenotype developed and how your body may respond to peptide-based interventions. These insights should be interpreted with a qualified healthcare provider.

The genetic test reveals predispositions in appetite-regulating and glucose-metabolic pathways, not exact medication response predictions. A patient carrying the FTO rs9939609 variant, for example, shows predisposition toward increased body weight regulation challenges—valuable context that may support provider conversations about treatment intensity or lifestyle integration, but not a guarantee of treatment success.

When combined with clinical biomarkers (glucose, lipids, blood pressure) and your complete medical history, genetic predisposition insights can support a more nuanced eligibility discussion with your provider. PlexusDx helps bridge the gap between genetic understanding and clinical decision-making, enabling personalized treatment conversations grounded in both data and medical expertise.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I qualify for GLP-1 treatment if my BMI is under 30?

Yes. BMI alone does not determine eligibility. Type 2 diabetes, documented cardiovascular disease, or significant weight-related comorbidities with BMI ≥27 may qualify. Your provider should evaluate your complete clinical picture, including glucose control and cardiovascular risk factors.

What metabolic markers does a provider typically assess?

Fasting glucose, HbA1c, blood pressure, lipid panel, waist circumference, and cardiovascular risk scores inform eligibility. These markers reveal metabolic dysfunction independent of weight and help stratify treatment appropriateness and expected benefits.

How do PlexusDx compounded GLP-1 options fit into eligibility discussions?

PlexusDx offers compounded semaglutide and tirzepatide from licensed 503A pharmacies starting at $149/mo. Once your provider confirms eligibility, these options provide cost-effective alternatives. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) may inform personalization within that framework.

What medical conditions disqualify someone from GLP-1 treatment?

Personal/family history of medullary thyroid cancer, MEN2, severe pancreatitis, and certain kidney/retinal conditions require specialist assessment. Pregnancy and uncontrolled psychiatric conditions warrant careful evaluation. Your provider must review your complete medical history before treatment consideration.

Does the Precision Peptide Genetic Test predict if GLP-1 will work for me?

No. The test reveals predispositions in peptide pathway variants (GLP1R, GIPR, FTO, MC4R), providing context for your metabolic profile. Genetic predisposition does not predict exact medication response. Clinical markers, provider evaluation, and individual health factors determine treatment suitability and outcomes.